515 related articles for article (PubMed ID: 32981857)
1. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study.
Albu S; Kumru H; Coll R; Vives J; Vallés M; Benito-Penalva J; Rodríguez L; Codinach M; Hernández J; Navarro X; Vidal J
Cytotherapy; 2021 Feb; 23(2):146-156. PubMed ID: 32981857
[TBL] [Abstract][Full Text] [Related]
2. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study.
Yang Y; Pang M; Du C; Liu ZY; Chen ZH; Wang NX; Zhang LM; Chen YY; Mo J; Dong JW; Xie PG; Wang QY; Liu B; Rong LM
Cytotherapy; 2021 Jan; 23(1):57-64. PubMed ID: 33218835
[TBL] [Abstract][Full Text] [Related]
3. Combining cell therapy with human autologous Schwann cell and bone marrow-derived mesenchymal stem cell in patients with subacute complete spinal cord injury: safety considerations and possible outcomes.
Oraee-Yazdani S; Akhlaghpasand M; Golmohammadi M; Hafizi M; Zomorrod MS; Kabir NM; Oraee-Yazdani M; Ashrafi F; Zali A; Soleimani M
Stem Cell Res Ther; 2021 Aug; 12(1):445. PubMed ID: 34372939
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Wharton Jelly-Derived Mesenchymal Stromal Cells and Their Conditioned Media in the Treatment of a Rat Spinal Cord Injury.
Chudickova M; Vackova I; Machova Urdzikova L; Jancova P; Kekulova K; Rehorova M; Turnovcova K; Jendelova P; Kubinova S
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547264
[TBL] [Abstract][Full Text] [Related]
5. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline.
Vaquero J; Zurita M; Rico MA; Aguayo C; Bonilla C; Marin E; Tapiador N; Sevilla M; Vazquez D; Carballido J; Fernandez C; Rodriguez-Boto G; Ovejero M;
Cytotherapy; 2018 Jun; 20(6):806-819. PubMed ID: 29853256
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton's Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance.
Vives J; Hernández J; Mirabel C; Puigdomenech-Poch M; Romeo-Guitart D; Marmolejo-Martínez-Artesero S; Cabrera-Pérez R; Jaramillo J; Kumru H; García-López J; Vidal-Samsó J; Navarro X; Coll-Bonet R
Cells; 2022 Jul; 11(14):. PubMed ID: 35883596
[TBL] [Abstract][Full Text] [Related]
7. Safe Reversal of Motor and Sensory Deficits by Repeated High Doses of Mesenchymal Stem Cells in a Patient with Chronic Complete Spinal Cord Injury.
Jamali F; Alqudah M; Rahmeh R; Bawaneh H; Al-Shudifat A; Samara O; Awidi A
Am J Case Rep; 2023 May; 24():e938576. PubMed ID: 37177780
[TBL] [Abstract][Full Text] [Related]
8. Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells.
Liu J; Han D; Wang Z; Xue M; Zhu L; Yan H; Zheng X; Guo Z; Wang H
Cytotherapy; 2013 Feb; 15(2):185-91. PubMed ID: 23321330
[TBL] [Abstract][Full Text] [Related]
9. A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells.
Arango-Rodríguez ML; Mateus LC; Sossa CL; Becerra-Bayona SM; Solarte-David VA; Ochoa Vera ME; Viviescas LTG; Berrio AMV; Serrano SE; Vargas O; Isla AC; Benitez A; Rangel G
Stem Cell Res Ther; 2023 Aug; 14(1):221. PubMed ID: 37626416
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and clinical applications of Wharton's jelly-derived mesenchymal stromal cells.
Liau LL; Ruszymah BHI; Ng MH; Law JX
Curr Res Transl Med; 2020 Jan; 68(1):5-16. PubMed ID: 31543433
[TBL] [Abstract][Full Text] [Related]
11. Image-guided percutaneous intralesional administration of mesenchymal stromal cells in subjects with chronic complete spinal cord injury: a pilot study.
Larocca TF; Macêdo CT; Souza BSF; Andrade-Souza YM; Villarreal CF; Matos AC; Silva DN; da Silva KN; de Souza CLEM; Paixão DDS; Bezerra MDR; Alves RL; Soares MBP; Dos Santos RR
Cytotherapy; 2017 Oct; 19(10):1189-1196. PubMed ID: 28760352
[TBL] [Abstract][Full Text] [Related]
12. Human umbilical cord mesenchymal stem cells to treat spinal cord injury in the early chronic phase: study protocol for a prospective, multicenter, randomized, placebo-controlled, single-blinded clinical trial.
Yang Y; Pang M; Chen YY; Zhang LM; Liu H; Tan J; Liu B; Rong LM
Neural Regen Res; 2020 Aug; 15(8):1532-1538. PubMed ID: 31997819
[TBL] [Abstract][Full Text] [Related]
13. Autologous mesenchymal stromal cell transplantation for spinal cord injury: A Phase I pilot study.
Satti HS; Waheed A; Ahmed P; Ahmed K; Akram Z; Aziz T; Satti TM; Shahbaz N; Khan MA; Malik SA
Cytotherapy; 2016 Apr; 18(4):518-22. PubMed ID: 26971680
[TBL] [Abstract][Full Text] [Related]
14. Significant Improvement of Acute Complete Spinal Cord Injury Patients Diagnosed by a Combined Criteria Implanted with NeuroRegen Scaffolds and Mesenchymal Stem Cells.
Xiao Z; Tang F; Zhao Y; Han G; Yin N; Li X; Chen B; Han S; Jiang X; Yun C; Zhao C; Cheng S; Zhang S; Dai J
Cell Transplant; 2018 Jun; 27(6):907-915. PubMed ID: 29871514
[TBL] [Abstract][Full Text] [Related]
15. Intra-bladder wall transplantation of bone marrow mesenchymal stem cells improved urinary bladder dysfunction following spinal cord injury.
Salehi-Pourmehr H; Rahbarghazi R; Mahmoudi J; Roshangar L; Chapple CR; Hajebrahimi S; Abolhasanpour N; Azghani MR
Life Sci; 2019 Mar; 221():20-28. PubMed ID: 30735734
[TBL] [Abstract][Full Text] [Related]
16. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series.
Honmou O; Yamashita T; Morita T; Oshigiri T; Hirota R; Iyama S; Kato J; Sasaki Y; Ishiai S; Ito YM; Namioka A; Namioka T; Nakazaki M; Kataoka-Sasaki Y; Onodera R; Oka S; Sasaki M; Waxman SG; Kocsis JD
Clin Neurol Neurosurg; 2021 Apr; 203():106565. PubMed ID: 33667953
[TBL] [Abstract][Full Text] [Related]
17. Use of Multiple Wharton Jelly Mesenchymal Stem Cell Transplants in Treatment of Incomplete Spinal Cord Injury: A Case Report.
Milczarek O; Kwiatkowski S; Swadźba J; Swadźba P; Kwiatkowska K; Majka M
Exp Clin Transplant; 2022 Sep; 20(9):878-882. PubMed ID: 35867006
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal transplantation of Wharton's jelly mesenchymal stem cells suppresses the NLRP1 inflammasome in the rat model of spinal cord injury.
Mohamadi Y; Noori Moghahi SMH; Mousavi M; Borhani-Haghighi M; Abolhassani F; Kashani IR; Hassanzadeh G
J Chem Neuroanat; 2019 Apr; 97():1-8. PubMed ID: 30703433
[TBL] [Abstract][Full Text] [Related]
19. Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury.
Mendonça MV; Larocca TF; de Freitas Souza BS; Villarreal CF; Silva LF; Matos AC; Novaes MA; Bahia CM; de Oliveira Melo Martinez AC; Kaneto CM; Furtado SB; Sampaio GP; Soares MB; dos Santos RR
Stem Cell Res Ther; 2014 Nov; 5(6):126. PubMed ID: 25406723
[TBL] [Abstract][Full Text] [Related]
20. CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury.
Bydon M; Dietz AB; Goncalves S; Moinuddin FM; Alvi MA; Goyal A; Yolcu Y; Hunt CL; Garlanger KL; Del Fabro AS; Reeves RK; Terzic A; Windebank AJ; Qu W
Mayo Clin Proc; 2020 Feb; 95(2):406-414. PubMed ID: 31785831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
